LLY
Eli Lilly and Company · Healthcare · Drug Manufacturers - General
すべての保有状況データ：追跡対象13Fマネージャーのみ、普通株ポジション、報告期間 Q2 2024
| 四半期 | 保有者 | Δ | 株数 | 報告済み評価額 | 新規 | 解消銘柄 |
|---|---|---|---|---|---|---|
| Q2 2026 | 193 | +4 | 671.92M | $804.91B | +6 | −1 |
| Q1 2026 | 191 | -3 | 666.59M | $613.20B | +1 | −5 |
| Q4 2025 | 193 | +2 | 707.04M | $758.81B | +3 | — |
| Q3 2025 | 27 | -3 | 329.88M | $251.63B | +2 | −6 |
| Q2 2025 | 28 | -1 | 307.45M | $239.60B | +2 | −3 |
| Q1 2025 | 26 | 0 | 140.32M | $115.83B | +1 | −1 |
| Q4 2024 | 26 | +1 | 145.00M | $111.91B | +3 | −2 |
| Q3 2024 | 24 | +2 | 109.89M | $97.29B | +2 | — |
| Q2 2024 | 22 | — | 112.43M | $101.75B | — | — |
| # | 運用会社 | 株数 | Δ株式数 | 時価 | そのウェイト | 保有中 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Capital World Investors ✦ | 21.81M | — | $19.75B | 3.2% | n/c | 1 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 20.65M | — | $18.70B | 2.2% | n/c | 1 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 20.65M | — | $18.70B | 2.2% | n/c | 1 | SEC ↗ |
| 4 | PRIMECAP Management ✦ | 19.62M | — | $17.76B | 12.9% | n/c | 1 | SEC ↗ |
| 5 | Geode Capital Management ✦ (パッシブ) | 17.01M | — | $15.35B | 1.3% | n/c | 1 | SEC ↗ |
| 6 | Geode Capital Management ✦ (パッシブ) | 17.01M | — | $15.35B | 1.3% | n/c | 1 | SEC ↗ |
| 7 | Norges Bank ✦ (パッシブ) | 11.00M | — | $9.96B | 1.5% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 10.78M | — | $9.76B | 1.7% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 10.78M | — | $9.76B | 1.7% | n/c | 1 | SEC ↗ |
| 10 | Wellington Management ✦ | 10.78M | — | $9.76B | 1.7% | n/c | 1 | SEC ↗ |
| 11 | Wellington Management ✦ | 10.78M | — | $9.76B | 1.7% | n/c | 1 | SEC ↗ |
| 12 | Wellington Management ✦ | 10.78M | — | $9.76B | 1.7% | n/c | 1 | SEC ↗ |
| 13 | Wellington Management ✦ | 10.78M | — | $9.76B | 1.7% | n/c | 1 | SEC ↗ |
| 14 | Wellington Management ✦ | 10.78M | — | $9.76B | 1.7% | n/c | 1 | SEC ↗ |
| 15 | Wellington Management ✦ | 10.78M | — | $9.76B | 1.7% | n/c | 1 | SEC ↗ |
| 16 | Wellington Management ✦ | 10.78M | — | $9.76B | 1.7% | n/c | 1 | SEC ↗ |
| 17 | Fisher Asset Management ✦ | 4.89M | — | $4.43B | 1.9% | n/c | 1 | SEC ↗ |
| 18 | Arrowstreet Capital ✦ | 1.61M | — | $1.46B | 1.3% | n/c | 1 | SEC ↗ |
| 19 | Tiger Global Management ✦ | 930.00K | — | $842.00M | 3.9% | n/c | 1 | SEC ↗ |
| 20 | Adage Capital Partners ✦ | 827.68K | — | $749.37M | 1.4% | n/c | 1 | SEC ↗ |
| 21 | Marshall Wace ✦ | 789.56K | — | $714.85M | 1.0% | n/c | 1 | SEC ↗ |
| 22 | Marshall Wace ✦ | 789.56K | — | $714.85M | 1.0% | n/c | 1 | SEC ↗ |
| 23 | Marshall Wace ✦ | 789.56K | — | $714.85M | 1.0% | n/c | 1 | SEC ↗ |
| 24 | Millennium Management ✦ | 532.04K | — | $481.70M | 0.4% | n/c | 1 | SEC ↗ |
| 25 | Citadel Advisors ✦ | 500.83K | — | $453.45M | 0.5% | n/c | 1 | SEC ↗ |
| 26 | Citadel Advisors ✦ | 500.83K | — | $453.45M | 0.5% | n/c | 1 | SEC ↗ |
| 27 | AQR Capital Management ✦ | 474.55K | — | $429.65M | 0.7% | n/c | 1 | SEC ↗ |
| 28 | AQR Capital Management ✦ | 474.55K | — | $429.65M | 0.7% | n/c | 1 | SEC ↗ |
| 29 | AQR Capital Management ✦ | 474.55K | — | $429.65M | 0.7% | n/c | 1 | SEC ↗ |
| 30 | AQR Capital Management ✦ | 474.55K | — | $429.65M | 0.7% | n/c | 1 | SEC ↗ |
| 31 | AQR Capital Management ✦ | 474.55K | — | $429.65M | 0.7% | n/c | 1 | SEC ↗ |
| 32 | D. E. Shaw & Co. ✦ | 237.22K | — | $214.78M | 0.3% | n/c | 1 | SEC ↗ |
| 33 | D. E. Shaw & Co. ✦ | 237.22K | — | $214.78M | 0.3% | n/c | 1 | SEC ↗ |
| 34 | Two Sigma Investments ✦ | 225.78K | — | $204.42M | 0.5% | n/c | 1 | SEC ↗ |
| 35 | Coatue Management ✦ | 207.05K | — | $187.46M | 0.7% | n/c | 1 | SEC ↗ |
| 36 | Coatue Management ✦ | 207.05K | — | $187.46M | 0.7% | n/c | 1 | SEC ↗ |
| 37 | Coatue Management ✦ | 207.05K | — | $187.46M | 0.7% | n/c | 1 | SEC ↗ |
| 38 | Coatue Management ✦ | 207.05K | — | $187.46M | 0.7% | n/c | 1 | SEC ↗ |
| 39 | Viking Global Investors ✦ | 144.18K | — | $130.53M | 0.5% | n/c | 1 | SEC ↗ |
| 40 | Bridgewater Associates ✦ | 95.74K | — | $86.68M | 0.5% | n/c | 1 | SEC ↗ |
| 41 | Dodge & Cox ✦ | 45.98K | — | $41.63M | 0.0% | n/c | 1 | SEC ↗ |
| 42 | GAMCO Investors ✦ | 35.83K | — | $32.44M | 0.4% | n/c | 1 | SEC ↗ |
| 43 | Gotham Asset Management ✦ | 11.95K | — | $10.82M | 0.1% | n/c | 1 | SEC ↗ |
「当該ウェイト」= そのマネージャーの報告済み13F株式評価額に占めるポジションの割合（確信度の指標）。✦ = キュレーション済みマネージャー。
新規買い手
| 今四半期は新規追跡買い手がいません。 |
ポジション解消済み
| 今四半期は追跡されたエグジットがありません。 |
市場全体のコンテキスト: 全13Fファイラー対象（SEC構造化データ、 Q1 2026): 4,323 保有者, 762.84M 株式数, $674.93B 報告済み. これは上記の追跡対象ユニバースの数値とは異なる、より古い期間のものであり、両者が混在することはありません。
この有価証券の追跡対象保有者が最も頻繁に保有する他の銘柄 — ファンダメンタルな関係ではなく、共同保有件数に基づきます。
市場内買い付け (P)
カバレッジ期間内にインサイダーによる市場内買い付けはありません。
市場内売却 (S)
Officer · 6.50K 株 · $7.64M
Officer · 2.00K 株 · $2.37M
Officer · 5.00K 株 · $5.95M
株式付与、権利行使および税務目的の株式差し引きは、買いや売りとして集計しません。 方法論
The Food and Drug Administration has cleared a new blood test from Roche and Eli Lilly designed to help identify…
ForbesThe Food and Drug Administration cleared a blood test for identifying Alzheimer's disease symptoms, which was developed…
WSJThe U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood test to help identify signs of…
ReutersThe once-daily pill was approved for patients with a body mass index of at least 30, or between 27 and 30 in the event…
WSJEli Lilly said on Monday it has launched its oral pill, Foundayo, in the UK for weight management and type 2…
Reuters